Buyback Spend for Novo Nordisk (NVO)
Buyback Spend for Novo Nordisk (NVO): headline value $1.39B · YoY -93.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
NVO
Currently viewingBuyback SpendSwitch metric
Latest period
$1.39B
YoY change
-93.1%
5Y CAGR
-39.3%
Peak year (2023)
$29.92B
Latest annual
$1.39B
Buyback Spend history chart for Novo Nordisk (NVO) from 1990 to 2025
Buyback Spend history table for Novo Nordisk (NVO) from 1990 to 2025
| Fiscal year | Period ended | Reported | Buyback Spend | YoY |
|---|---|---|---|---|
| 2025 | $1.39B | -93.1% | ||
| 2024 | $20.18B | -32.6% | ||
| 2023 | $29.92B | +24.2% | ||
| 2022 | $24.09B | +23.9% | ||
| 2021 | $19.45B | +15.4% | ||
| 2020 | $16.86B | +9.9% | ||
| 2019 | $15.33B | -1.5% | ||
| 2018 | $15.57B | -7.6% | ||
| 2017 | $16.84B | +11.9% | ||
| 2016 | $15.06B | -12.4% | ||
| 2015 | $17.20B | +17.2% | ||
| 2014 | $14.67B | +5.3% | ||
| 2013 | $13.92B | +17.0% | ||
| 2012 | $11.90B | +12.3% | ||
| 2011 | $10.60B | +11.5% | ||
| 2010 | $9.50B | +45.9% | ||
| 2009 | $6.51B | +37.7% | ||
| 2008 | $4.73B | -2.4% | ||
| 2007 | $4.84B | +61.4% | ||
| 2006 | $3.00B | -0.4% | ||
| 2005 | $3.01B | +50.8% | ||
| 2004 | $2.00B | +22.9% | ||
| 2003 | $1.63B | +325.4% | ||
| 2002 | $382.20M | +1425.0% | ||
| 2001 | $25.06M | -99.0% | ||
| 2000 | $2.47B | +70.5% | ||
| 1999 | $1.45B | -26.4% | ||
| 1998 | $1.97B | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — | ||
| 1990 | $0 | — |
Buyback Spend values are taken from Novo Nordisk's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in DKK as filed.
Analysis
2025's annual buyback spend for Novo Nordisk (NVO) came in at $1.39B – plunged 93.1% year-over-year.
Novo Nordisk buyback spend compound annual growth for the 2020–2025 (5 years) window is -39.3%, with a net decline across the window.
Novo Nordisk buyback spend peaked at $29.92B in 2023; the latest annual figure is $1.39B in 2025 (95.4% below peak).
Across the available history, buyback spend reached its high of $29.92B in 2023 and its low of $0 in 1990.
Novo Nordisk (NVO) sits 6th of 8 Healthcare peers we track on this metric, against a peer median of $3.55B.
Novo Nordisk Buyback Spend by Year
Novo Nordisk Buyback Spend 2025: $1.39B
Novo Nordisk buyback spend in 2025 was $1.39B, plunged 93.1% below 2024.
Novo Nordisk Buyback Spend 2024: $20.18B
Novo Nordisk buyback spend in 2024 was $20.18B, plunged 32.6% below 2023.
Novo Nordisk Buyback Spend 2023: $29.92B
Novo Nordisk buyback spend in 2023 was $29.92B, grew 24.2% from 2022. This figure represents the highest annual value in the available history.
Novo Nordisk Buyback Spend 2022: $24.09B
Novo Nordisk buyback spend in 2022 was $24.09B, grew 23.9% from 2021.
Novo Nordisk Buyback Spend 2021: $19.45B
Novo Nordisk buyback spend in 2021 was $19.45B.
See more financial history for Novo Nordisk (NVO).
Sector peers — Buyback Spend
Companies in the same sector as Novo Nordisk, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $5.54B | Healthcare |
| Merck & Co., Inc. (MRK) | $5.08B | Healthcare |
| Eli Lilly and Company (LLY) | $4.11B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $3.00B | Healthcare |
| AbbVie Inc. (ABBV) | $980.00M | Healthcare |
| AstraZeneca PLC (AZN) | $719.66M | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
Frequently asked questions
What is Novo Nordisk's buyback spend?
Latest reported buyback spend for Novo Nordisk (NVO) is $1.39B (period ending December 31, 2025).
How has Novo Nordisk buyback spend changed year-over-year?
Novo Nordisk (NVO) buyback spend changed -93.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Novo Nordisk buyback spend?
Novo Nordisk (NVO) buyback spend compound annual growth rate is -39.3% over the most recent 5 years available.
When did Novo Nordisk buyback spend hit its highest annual value?
Novo Nordisk buyback spend reached its highest annual value of $29.92B in 2023.
What was Novo Nordisk buyback spend in 2024?
Novo Nordisk (NVO) buyback spend in 2024 was $20.18B.
What was Novo Nordisk buyback spend in 2025?
Novo Nordisk (NVO) buyback spend in 2025 was $1.39B.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
NVO Overview
Company profile, financial tools, and key metrics
NVO Revenue Counter
Earns 9,800 DKK every second. See per minute, hour, and day.
NVO Earnings Counter
Earns 3,248 DKK per second net profit. See per minute, hour, and day.
NVO Economic Scale
Exceeds Cambodia's GDP. Compare with world economies.
NVO What If Invested
What if you had invested $1,000? See historical returns from any date.
NVO How It Makes Money
Discover visual breakdown of 309.06B DKK in revenue — where it comes from and where it goes.
NVO Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
NVO Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
NVO Daily Price Character
Balanced · 47.3% historical win rate (green days). Streaks & record days.
NVO Buybacks
0.10% TTM buyback yield. Shareholder yield & SBC comparison.
NVO Stock Split History
5 splits on record. Dates, ratios, and cumulative multiple.
NVO Dividend Profile
Yield: 4.62%. Safety: 5/8. See full history.
NVO Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
NVO Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.